Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Journal of Neuropathology and Experimental Neurology|November 29, 2020
GLI3 Is Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated MedulloblastomaManabu Natsumeda, Hiroaki Miyahara, Junichi Yoshimura, et al.
BMJ Open|April 24, 2023
Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised studyFumiyuki Yamasaki, Hirotaka Fudaba, Kenichiro Asano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade GliomaJo Sasame, Naoki Ikegaya, Masahito Kawazu, et al.
Brain Tumor Pathology|March 11, 2021
Topoisomerase IIβ immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer GroupHiroaki Miyahara, Manabu Natsumeda, Yonehiro Kanemura, et al.
Molecular Cell|February 5, 2025
SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosisAkane Ogawa, Keiichi Izumikawa, Sota Tate, et al.
Neuro-Oncology|November 5, 2022
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114CKazuhiko Mishima, Ryo Nishikawa, Yoshitaka Narita, et al.
Neuro-Oncology Advances|March 13, 2026
Treatment initiation by positive liquid biopsy alone in primary central nervous system lymphoma: A retrospective analysis of a multi-institutional studyMasaki Mitobe, Satoshi Shibuma, Haruhiko Takahashi, et al.
International Journal of Clinical Oncology|November 11, 2024
Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resectionMasayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, et al.
Cancer Research|October 17, 2020
A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System LymphomaKensuke Tateishi, Yohei Miyake, Masahito Kawazu, et al.
Neuro-Oncology|November 4, 2024
Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up studyHirokazu Takami, Masao Matsutani, Tomonari Suzuki, et al.
Pageof 11